encouraging phase two outcomes for a new oral Alzheimer's medication.

Published Date: 28 Oct 2023

Based on early data, an investigational dual PPAR agonist modifies the pathology of Alzheimer's disease and exhibits cognitive benefit in adults with mild-to-moderate disease and high plasma pTau-217 ratio.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

2.

Detecting pancreatic cancer through changes in body composition and metabolism

3.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.

4.

The pandemic had little impact on mental health symptoms.

5.

Men over 75 years old may be significantly more likely to commit suicide if they have cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot